KRAS G13D sensitivity to neurofibromin-mediated GTP hydrolysis

RAS isoforms and mutations in cancer at a glance

(2016) G. Aaron Hobbs et al.   JOURNAL OF CELL SCIENCE

Response to Cetuximab With or Without Irinotecan in Patients With Refractory Metastatic Colorectal Cancer Harboring theKRASG13D Mutation: Australasian Gastro-Intestinal Trials Group ICECREAM Study

(2016) Eva Segelov et al.   JOURNAL OF CLINICAL ONCOLOGY

The Structural Basis of Oncogenic Mutations G12, G13 and Q61 in Small GTPase K-Ras4B

(2016) Shaoyong Lu et al.   Scientific Reports

Biochemical and Structural Analysis of Common Cancer-Associated KRAS Mutations

(2015) J. C. Hunter et al.   MOLECULAR CANCER RESEARCH

Mutational heterogeneity in cancer and the search for new cancer-associated genes

(2013) Michael S. Lawrence et al.   NATURE

Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal

(2013) J. Gao et al.   Science Signaling

Collaboration gets the most out of software

(2013) Andrew Morin et al.   eLife

Identification of Mutant K-Ras-dependent Phenotypes Using a Panel of Isogenic Cell Lines

(2012) Steffan Vartanian et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Association ofKRASG13D Tumor Mutations With Outcome in Patients With Metastatic Colorectal Cancer Treated With First-Line Chemotherapy With or Without Cetuximab

(2012) Sabine Tejpar et al.   JOURNAL OF CLINICAL ONCOLOGY

Mutant KRAS Codon 12 and 13 Alleles in Patients With Metastatic Colorectal Cancer: Assessment As Prognostic and Predictive Biomarkers of Response to Panitumumab

(2012) Marc Peeters et al.   JOURNAL OF CLINICAL ONCOLOGY

Effect of KRAS Oncogene Substitutions on Protein Behavior: Implications for Signaling and Clinical Outcome

(2012) Nathan T. Ihle et al.   JNCI-Journal of the National Cancer Institute

Ras Stabilization Through Aberrant Activation of Wnt/ -Catenin Signaling Promotes Intestinal Tumorigenesis

(2012) W.-J. Jeong et al.   Science Signaling

The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.

(2012) Ethan Cerami et al.   Cancer Discovery

Are all KRAS mutations created equal?

(2011) Thomas E Stinchcombe et al.   LANCET ONCOLOGY

Features and development ofCoot

(2010) P. Emsley et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

PHENIX: a comprehensive Python-based system for macromolecular structure solution

(2010) Paul D. Adams et al.   ACTA CRYSTALLOGRAPHICA SECTION D-BIOLOGICAL CRYSTALLOGRAPHY

Association of KRAS p.G13D Mutation With Outcome in Patients With Chemotherapy-Refractory Metastatic Colorectal Cancer Treated With Cetuximab

(2010) Wendy De Roock et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Regulation of the inducible nuclear dual-specificity phosphatase DUSP5 by ERK MAPK

(2009) Anna Kucharska et al.   CELLULAR SIGNALLING

Implications for KRAS status and EGFR-targeted therapies in metastatic CRC

(2009) Nicola Normanno et al.   Nature Reviews Clinical Oncology

Fluoride complexes of oncogenic Ras mutants to study the Ras-RasGAP interaction

(2008) Lothar Gremer et al.   BIOLOGICAL CHEMISTRY

The GAP arginine finger movement into the catalytic site of Ras increases the activation entropy

(2008) C. Kotting et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Reciprocal regulation of extracellular signal regulated kinase 1/2 and mitogen activated protein kinase phosphatase-3

(2008) Nicholette A. Zeliadt et al.   TOXICOLOGY AND APPLIED PHARMACOLOGY